October 2026 AOM: Ibogaine and the Bicameral Mind

We warmly welcome Jonathan Dickinson, author of Ibogaine and the Bicameral Mind: The Transformational Potential of the World’s Most Complex Psychedelic Medicine, as our featured author this month. Jonathan is CEO and co-founder of Ambio Life Sciences and has spent more than fifteen years working with ibogaine in clinical practice, traditional medicine and research.

Jonathan’s book explores ibogaine, the powerful psychoactive compound derived from the root bark of the central African iboga shrub. It draws together three strands: the science of how ibogaine acts on the brain and body, the historical and spiritual context of Bwiti, and its practical use in modern clinical settings.

In his article, Jonathan traces ibogaine’s history from its ancient ceremonial use in the rainforests of Gabon to the clinics of Mexico and, most recently, the Oval Office. Drawing on Julian Jaynes’ theory of the “bicameral mind”, he asks whether modern psychiatry is ready to make room for ibogaine, which is emerging as one of the most promising tools in neuroregenerative medicine, addiction recovery and trauma treatment.

Interact with Jonathan on our AoM Forum here.

Ibogaine is a fine white powder like so many others: odorless, bitter, otherwise nondescript. However, when it is encapsulated and introduced to the human body and mind, it becomes something quite unique and extraordinarily powerful. From the shadows of the cultural fringes and anonymity of prehistory, ibogaine’s nature is still largely mysterious to us, and our relationship to this “Mount Everest of psychedelics,” while deep, is still rapidly evolving as we learn more about the scope of its potential.

My recent book, Ibogaine and the Bicameral Mind, traces a line through ibogaine’s strange story, one shaped by my own experiences and proximity to those who have been cautiously negotiating its place in Western civilization through medical protocols and political advocacy. It examines ibogaine’s origins in the roots of Tabernanthe iboga, a shrub native to the rainforests of Gabon, where the powdered root bark has been used for millennia in rituals of initiation and healing, followed by its extraction by early European explorers.

Tabernanthe iboga (Apocynaceae), Limbe Botanical Garden, Cameroon. Image by Marco Schmidt. (CC-BY SA 2.5)

The Modern History of Ibogaine

Ibogaine has the unique capacity to mitigate most of the difficult withdrawal symptoms from opioids, something that no other known medicine does. On top of that, it helps to reduce long-standing post-acute withdrawal and cravings and supports addiction recovery for many other substances. Despite this unparalleled early promise, a round of clinical trials in the United States in the 1990s was derailed by reports of ibogaine-related deaths overseas, as well as litigation among the investigators. Pushed underground, some of those who experienced ibogaine’s benefits firsthand laid the groundwork for a clinical network in Mexico that continues to grow and expand in scope decades later.

Adverse events like the overseas deaths were rare but known potential outcomes. When I arrived in Mexico in late 2009, I spent years apprenticing at leading ibogaine clinics before compiling a document called the Clinical Guidelines for Ibogaine-Assisted Detoxification to address ibogaine’s medical risks, drawing on forensic medical research that helped to identify risk factors. We argued that these risks could not be eliminated completely, but could be greatly reduced with cardiac screening and monitoring, as well as drug testing and careful medication management around the treatment.

In 2021, I co-founded Ambio Life Sciences, now the leading clinic operator globally, treating a large number of combat veterans and athletes with traumatic brain injuries (TBIs), as well as a diverse range of other civilians from the spiritually curious to those wrestling with neurodegenerative conditions like Parkinson’s and multiple sclerosis. What we’ve learned and helped to demonstrate through collaborations with leading research institutions is that ibogaine can stimulate cellular regeneration in damaged tissue, again, where no other known medical intervention has shown any promise. One breakthrough publication from Stanford University linked this to substantial and lasting reductions in symptoms of neurological disability, PTSD, depression and anxiety, which often accompany TBIs.

On April 18, 2026, squarely between the time that I submitted the book’s final chapter and its release last month, President Donald Trump issued an executive order accelerating the development and approval process for psychedelic medicines. Sitting in the Oval Office, flanked by a Navy SEAL I knew personally, and citing a Stanford research paper describing results from Ambio’s treatments, the most powerful political official in the world singled out ibogaine as a national research priority. Since then, federal agencies have begun allocating large pools of funding to accelerate medical research, and the FDA has indicated a willingness to revisit ibogaine’s technical complications pragmatically.

I can’t say I saw this moment coming, not at this velocity. But I did know that the involvement of the special operations veterans would transform the story that people understood about ibogaine, and therefore its trajectory through the world. I saw the potential for the familiar pitfalls amongst newly minted advocates or prospective entrants to the field on a much larger scale, and I began to write. I hope that this book can provide some of the depth, color, and context of what came before.

Strange, Dream-like Phenomena

In a traditional context, the purpose of undergoing an initiation experience is to absorb knowledge that must be embodied, not merely learned. When I began to work with ibogaine, I found an obvious barrier between those who were initiated to its effects by taking it themselves, and those who researched it scientifically.

One benign indication of this gap was the “buzzing” sound often described in scientific literature, which purportedly accompanied the onset of ibogaine’s effects. The first time that I took ibogaine at a Tijuana ibogaine clinic in 2009, I heard the sound of a helicopter flying out in front of me and felt the rotor wash of the blades chopping through the air, a much more substantial vibration than the kind of “buzzing” you imagine after experiencing tinnitus. Others described bees, static or other sounds, but often with a spatial and tactile orientation. This kind of qualitative nuance became helpful later in imagining ibogaine’s neurological mechanisms.

Visionary art study directed at meditative practices for illustration. Image by David S Soriano (CC-BY-SA 4.0)

The term oneirogenic (“dream generating”) is a useful way to distinguish ibogaine’s effects from those of other psychedelics. It originated in psychiatric terminology used to describe visions, voices and other phenomena that appeared without causing other alterations to an individual’s sense of self or normal thought patterns. This helped account for the notable lack of “ego dissolution” common to other classic tryptamine molecules. On ibogaine, people remained aware of themselves and their surroundings, even when they were strongly compelled to lie down, close their eyes, and turn inward.

Other common motifs, like the idea of a “life review,” where patients sorted through memories from childhood, left people with genuinely confused expectations. It happened in some cases, but very rarely. Most people saw much stranger psychoanalytic content, and a not insignificant 25-33% saw next to nothing at all. They had physically challenging, even grueling experiences that left them without any immediate insights or resolutions. Either way, the content didn’t seem to have much of a bearing on the treatment outcome. Most still had quieter minds and experienced an increased sense of personal agency in the days, weeks and months that followed.

Meanwhile, my own research began to highlight an important dialogic mechanism in the ibogaine experience. People often described seeing or interacting with guides or antagonists, sometimes in protracted dialogues, questioning and answering from the vantage point of a slightly detached “witness” of their inner landscape. In Africa, during initiations I underwent across various branches of Bwiti, the iboga-centered spiritual tradition of Gabon, I saw traditional practitioners in village settings demonstrate impressive fluency in the syntax of the subconscious, to the point that experienced Ngangas (Bwiti ritual specialists) could sometimes steer initiates toward certain types of information. This could involve prompting initiates with instructions on how to navigate the dream landscape, or with questions designed to elicit answers that would provide foresight for the individual or their village as a whole.

An Ancient Problem-Solving Mechanism

In my search for other common denominators to make sense of an often-confusing state, I encountered the compelling work of Julian Jaynes and his book, The Origin of Consciousness in the Breakdown of the Bicameral Mind (1976). An evolutionary psychologist with affiliations at Princeton and Yale, Jaynes controversially posited that our ancient ancestors were not conscious, at least not in the sense that we experience today. Instead, they perceived, reasoned, and navigated the world with a largely different form of cognition.

Consciousness, for Jaynes, was defined as the capacity to model reality and test hypotheses. To the extent that our inner maps correlate to the relationships and physics of our surrounding reality, we can engineer solutions to technical problems, propelling the rapid accumulation of technology and computation.

Image from Julian Jaynes Society (Public Domain)

Our ancestors, instead, may have experienced a “bicameral mind,” meaning a mind with two “chambers.” On one side sat their identity, with which they navigated the world, guided largely by a know-how informed by habit and tradition. Faced with novel decision stress, the other chamber developed creative solutions that often arrived as the audible counsel of an external voice, which they heard and obeyed. This, Jaynes felt, accounted for the linguistic interventions of the dead, spirits, gods, and even the God of monotheism.

Jaynes’ theory provided a useful way to describe some of ibogaine’s stranger phenomenology and also its potential value. Sometimes, the information shared by these guides and antagonists helped people to navigate situations in their lives, but it often didn’t lead to any immediate insight or resolution. Instead, it was more common that people described a better connection to their instincts and a sense of easeful inner guidance after treatment. This helped to shift the focus away from the content of the experience to a valuable transformation in how people processed information.

The value of the bicameral mind as a reference point for ibogaine does not necessarily hinge on the historical accuracy of Jaynes’ theory, which imagined modern consciousness emerging from the breakdown of this earlier state. But his psycho-archaeological lens does raise the question: what if our technological approach to health is simply poorly conceived to address the actual challenge of mental health by overly objectifying the world? Most personal and interior challenges engage a much more subjective realm, demanding that we exercise agency, moral direction, and instinctual awareness in the face of ambiguity. In other words, overcoming these challenges requires us to connect more deeply with our own inner guidance.

Chemical structure of ibogaine. Image by Calvero. (Public Domain)

Ancient Futures in Mental Health?

For thousands of years, people have tried to retain some form of access to the bicameral state through ritual, mantra, prayer, or other practices that overwhelm and bypass conscious circuits. People who were thought to have contact with God, spirits, or ancestors were as feared as they were revered.

However, while this quest has defined spiritual pursuits for millennia, similar phenomenology has been not only overlooked but pathologized and medicated by psychiatry. This presents an interesting conundrum for ibogaine research. To what degree will the medical and scientific fields expect ibogaine to perform like familiar pharmaceutical interventions, and to what extent is the culture capable of integrating more ancient perspectives on solving our intractable interior challenges?

The history of psychiatry has been particularly fraught, with rare incremental breakthroughs surrounded by sometimes horrific and more than occasionally harmful misunderstandings about how best to intervene in the subjective and behavioral realms of conscious experience.

We now sit at a precipice, where the highest political offices are open to embracing radical changes if they can demonstrate empirical improvements in our standards of care. The question will be: as bureaucrats and medical professionals entrenched in their respective institutional landscapes try to wrestle with ibogaine, will we continue to imagine interventions as mechanistic surgeries to correct broken electrochemical circuits, or will we begin to open to aspects of ourselves and of nature that have been systematically criminalized or suppressed by our civilization to date?